TGM-148 / Tangram Therapeutics - LARVOL DELTA

e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025 (GlobeNewswire) - "e-therapeutics plc...announced today that it will present new preclinical data demonstrating efficacy and safety of ETX-148 in murine models of haemophilia A and B at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), 4th-7th February 2025. ETX-148 is being developed for the treatment of bleeding disorders and is currently progressing through IND-enabling studies, with an IND submission anticipated during 2026."

IND • Preclinical • Hemophilia A • Hemophilia B

Efficacy and Safety of ETX-148 in Murine Models of Haemophilia A and B (EAHAD 2025) - No abstract available

Preclinical • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases